Phase 0/1 clinical trial (CleavHER trial) of TGW211 initiated, sponsored by the Radboud University Medical Center in the Netherlands; enrollment of first patients expected by end of 2025 and ...
NIJMEGEN, Netherlands and BOSTON, Sept. 9, 2025 /PRNewswire/ -- Tagworks Pharmaceuticals BV ("Tagworks"), a clinical-stage precision oncology company using its proprietary Click-to-Release treatment ...
TGW101 is a next-generation, first-in-class ADC targeting TAG-72 with an MMAE payload, developed based on Tagworks proprietary Click-to-Release linker chemistry; TGW101 is the first bioorthogonal, in ...
Biotech industry veteran to lead Tagworks as the company prepares to bring its novel platform and lead antibody-drug conjugate (ADC) program for solid tumors into the clinic in 2025 Founding CEO Marc ...
The Hillman Companies, Inc. (NYSE-Amex: HLM_P) (the “Company” or “Hillman”), announced today that its subsidiary, The Hillman Group, Inc. entered into a purchase agreement to acquire all of the ...
NIJMEGEN, Netherlands and BOSTON, Oct. 15, 2025 /PRNewswire/ -- Tagworks Pharmaceuticals BV ("Tagworks"), a clinical-stage precision oncology company using its proprietary Click-to-Release treatment ...
TGW101 is a next-generation, first-in-class ADC targeting TAG-72 with an MMAE payload, developed based on Tagworks proprietary Click-to-Release linker chemistry; TGW101 is the first bioorthogonal, in ...
TGW211 is a next-generation, first-in-class HER2-directed radioimmunoconjugate developed based on Tagworks' proprietary Click-to-Release – bioorthogonal, in vivo click chemistry – linker platform ...
TGW101 is a next-generation, first-in-class ADC targeting TAG-72 with an MMAE payload, developed based on Tagworks proprietary Click-to-Release linker chemistry; TGW101 is the first bioorthogonal, in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results